All In Biotech

Drug Trial Radar · NCT05102123

PeRiopEratiVE SmokiNg CessaTion Trial

Last checked: Nov 20, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,720 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,720

Planned (sponsor's estimate)

Start

Jan 15, 2024

Primary completion

Jul 1, 2026

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.

Conditions

  • Smoking (Tobacco) Addiction
  • Smoking Cessation

Interventions

  • CytisineDrug

    Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation

  • Video MessagingBehavioral

    Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Smoking CessationTime frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Kingston Health Science Centre with its research institute Kingston General Health Research Institute

    Kingston, Ontario, Canada

  • Lawson Health Research Institute: London Health Sciences Centre Research Inc. and the Lawson Research Institute

    London, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.